Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must sign an Informed Consent Form~* In remission from past HE~* Appropriate birth control measures~* More than or equal to 18 years of age~* Must be potential for benefit from treatment~* Recent HE episodes~* Capable and willing to comply with all study procedures~* Participant has support network~Exclusion Criteria:~* Significant medical conditions or Investigator decision not to include the participant~* Allergies to the study drug or similar drugs~* Laboratory abnormalities~* Recent participation in another clinical trial~* Problems experienced in a previous HE trial~* Pregnant or at risk of pregnancy~* Recent alcohol consumption~* Active or latent bacterial or viral Infections~* Bowel issues~* Recent Active Cancer~* On a prohibited medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).